

International Concurrent Workshop Clinical 9

RA strategy

Day 2 April 22, 16:15 - 17:15 Room 4

Chair: Hiroko Kobayashi

Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Japan

ICW-C9-1 Sero-positivity for rheumatoid factor is an independent predictor for achievement of good EULAR response at 24 weeks in ACPA highpositive RA patients treated with abatacept: Results from Japanese multicenter registry

Nobunori Takahashi

Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

ICW-C9-2 Early improvement of musculoskeletal ultrasound findings can predict future clinical response to certolizumab pegol in patients with rheumatoid arthritis

Takanori Fujimura

The Center for Rheumatic Diseases, Nara Medical University, Kashihara, Japan

ICW-C9-3 Attaining comprehensive disease remission (CDR) in the first treatment year is most important for predict of sustaining CDR in a long term in rheumatoid arthritis treatment

Ichiro Yoshii

Department of Orthopedic Surgery and Rheumatology, Yoshii Hospital, Japan

ICW-C9-4 Reducing and spacing after achieving sustained remission in rheumatoid patients in real world from local biologics registry

Yuya Takakubo

Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Japan

ICW-C9-5 Prospective Study about 6-week Extended Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance

Jun Kikuchi

Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Japan

ICW-C9-6 Discontinuation of tofacitinib after achieving low disease activity (LDA) in patients with established rheumatoid arthritis (RA) : A prospective, multicenter, observational study

Satoshi Kubo

The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan